Completed strategic pivot from R&D focus to commercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned ...

CRISPR-based technology is advancing rapidly, driving international competition. Its promise to transform medicine is colliding with political and social realities, even as applications expand.

Completed strategic pivot from R&D focus to commercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relationsAdvanced mu ...

The global biotechnology market is expected to grow at a rate of 13-15% over the next five years. Key drivers of this growth ...

In this interview, Dr. Kelemen discusses the advantages of lipid-based delivery systems and their potential to expand the ...

Since 1901, the Nobel Prize has honored ideas that changed the way we live. From discoveries that made headlines to ...

Outcomes validate the company’s PTAP platform as a foundation for a rapid, adaptable antiviral modality across animal and ...

Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor ...

Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...

By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...

Genetic medicines-focused Scribe Therapeutics is racing toward the clinic on the heels of a preclinical data drop for three ...